Pharma deal to ramp up retail reach in Australia

Pharmacor and Celltrion are boosting their strategic partnership, with the companies seeing the deal as a stepping-stone to further collaboration across a broader pipeline.

Pharmacor will provide commercial support within the Australian retail pharmacy market for Celltrion's Stoboclo, a biosimilar of Amgen's osteoporosis drug Prolia, which is now handled by Arrotex.

"We are delighted to strengthen our relationship with Celltrion through this new collaboration," Pharmacor CEO, Richard Mlynarcik. "Having worked together successfully across other molecules, this next chapter is a natural progression of our partnership.

To see the whole article please log in.

James Quintana Pearce

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here